Yale BioHaven Entrepreneurship Seminars Presents Vascular Insights:"Simplified Treatment For Varicose Veins"
Main Category: VascularAlso Included In: Blood / Hematology; Conferences
Article Date: 05 Nov 2007 - 3:00 PST
The Yale BioHaven Entrepreneurship Seminars continues its fall schedule with a program on Vascular Insights, LLC on Tuesday November 13 from 4 to 5 p.m. in the Anlyan Center Auditorium, Yale School of Medicine, 300 Cedar Street. The series organized by the Yale Office of Cooperative Research and Connecticut United for Research Excellence (CURE).
Vascular Insights, LLC is a New Haven area start-up company founded to develop, manufacture and market the ClariVein-VA vascular ablation devices to treat varicose vein disease. The system they are developing combines technology licensed from Yale and its own intellectual property in a simplified procedure that uses a single, disposable product for elimination of varicose veins.
According to the founders of Vascular Insights, the company's procedure will eliminate the need for anesthesia, hospitalization or surgery, and will cause less damage to surrounding tissue and nerves than current therapies. They say this would translate into considerably reduced convalescence, complications and pain for patients.
The featured speakers will be co-founders John Marano, president and CEO of Vascular Insights; and Michael Tal, M.D., chief medical advisor of Vascular Insights and associate professor of radiology at Yale University School of Medicine.
Varicose vein disease affects an estimated 75 to 150 million people in North America and Western Europe, and that it is one of the least treated chronic conditions in the developed world.
"The market for treatment of varicose vein disease is just waiting for a good solution," said Marano. "Currently only about 1% to 2% of sufferers actually obtain treatment, in large part due to the cost, and the unacceptable nature and trauma of existing treatments - which include surgery and laser destruction of tissue."
With seed funding in place, the company is currently seeking strategic partners to share risk and accelerate product development.
Refreshments and networking will follow the seminar from 5 to 7 p.m. Registration is free, but advanced registration is required. To RSVP, send an e-mail to biohaven@yale.edu. A flyer about all events in the series is on line at http://curenet.org/download/biohaven.pdf . Directions to the event are available online at http://info.med.yale.edu/maps/cab.html.
Yale BioHaven Entrepreneurship Seminars are sponsored by the Yale Office of Cooperative Research, Connecticut United for Research Excellence (CURE), Wiggin and Dana, LLP, Elm Street Ventures, and Price Waterhouse Coopers, PC. with support from Yale Entrepreneurial Society and Yale Biotechnology & Pharmaceutical Society. For further information on the seminar, please contact Tracy Huang at tracy.huang@yale.edu .
http://www.yale.edu
Visit our vascular section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/87661.php>
APA
http://www.medicalnewstoday.com/releases/87661.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Mr
posted by Brian O'Neill on 14 Jan 2008 at 8:07 amFirst, good to see new product/approach to a medical problem that is so widespread, and from which I 'suffer'. Next. as a British psychologist involved in business and management, I find it intriguing to see varicose veins as 'a market' and a business opportunity.
This is, of course, the US way but our way is socialized medicine. Though committed to our Brit NHS principles and system (don't listen to Guiliani), I very much appreciate the importance of market forces and private sector innovation, as exemplified by this advertisement. How can both be combined and channelled to the advantage of both investor and public?
I would have given the advertisement 5, rather than 4, if it had given some indication of the nature of the new treatment. Risk being open.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




